Eli Lilly is a leader in the market for GLP-1 medicines. The company's Zepbound, indicated for weight loss, is racking up billions in quarterly sales. Its only real competitor in weight management is ...

Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...

A restful night’s sleep is vital to a healthy lifestyle but an Indiana physician said most Americans are not getting enough ...

Eli Lilly's Mounjaro and Zepbound drove Q2 2025 revenue up 38% and EPS up 92% YoY. Read why LLY stock's recent 20% pullback ...

There’s a new kind of nosy parker on the rise in the United States, a person who thinks it’s fine to blurt out “Are you on ...